As a Free StocksGuide user, you can view scores for all 7,006 stocks worldwide.
15 Analysts have issued a Pieris Pharmaceuticals, Inc. forecast:
15 Analysts have issued a Pieris Pharmaceuticals, Inc. forecast:
Mar '25 |
+/-
%
|
||
Revenue | - - |
-
|
|
Gross Profit | - - |
-
|
|
EBITDA | - - |
-
|
EBIT (Operating Income) EBIT | -17 -17 |
15%
15%
|
Net Profit | -21 -21 |
28%
28%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Pieris Pharmaceuticals, Inc. is a clinical-stage biotechnology company, which engages in the discovery and development of Anticalin-based drugs. Its pipeline includes immuno-oncology, respiratory, and anemia and other disease areas. The company was founded by Claus Schalper and Arne Skerra in 2001 and is headquartered in Boston, MA.
Head office | United States |
CEO | Wesley Kaupinen |
Founded | 2001 |
Website | palvellatx.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.